Antiaging
Literature Review
As discussed in the
article above increased urinary catecholamines (dopamine, norepinephrine,
and epinephrine) are a marker for functional decline and mortality
(increased risk of death). Until the research work of NeuroResearch Clinics
no one knew what these findings meant other than being novel. As discussed on
other pages of this web site, people with increased catecholamines in their
urine who are not taking catecholamine precursors (amino acids) as suffering
from "phase 1" inappropriate excretion of catecholamines. In antiaging
treatment this problem is easily corrected with the administration of
properly balanced amino acid precursors guided by urinary
organic cation transporter neurotransmitter optimization as indicated. At present NeuroResearch Clinics view
the correction of high levels of neurotransmitters in the urine as being
similar to high blood pressure, it is a risk factor, a marker for functional decline
and mortality as patients grow older. Urinary organic cation transporter neurotransmitter optimization in
the elderly (65 years and older) should be at the heart of every
antiaging program.
Its no secret, NeuroResearch Clinics uses the nutrients 5-HTP, tyrosine, levodopa, and cysteine with neurotransmitter tests as indicted to treat disease. Proper use these simple ingredients is not simple. Occasionally a patient will say, "Why should I take that, I buy it in a health food store?" People off the street buying neurotransmitter nutrients in a health food store is like going to an art store and buying oil paints then going home and expecting to paint like a master artist with no previous painting experience. This is sophisticated neurotransmitter medical treatment. Nutrients have tremendous neurotransmitter treatment potential due to the chemical properties. This neurotransmitter is only fully realized by the trained professional. The NeuroResearch Clinics Peer Reviewed research The research findings of NeuroResearch Clinics have not been ignored. The University of Minnesota Medical School is writing a series of papers on the organic cation transporter neurotransmitter optimization research of NeuroResearch Clinics. The first of a series of papers by University of Minnesota Medical School based on the organic cation transporter neurotransmitter optimization research of NeuroResearch was published in "The Journal of NeuroPsychiatry" May 1, 2009. Ingrid Kohlstadt, MD of Johns Hopkins in her new medical text book released February 7, 2009 included a chapter on depression written by Marty L. Hinz, MD President Clinical Research NeuroResearch Clinics outlining in depth the proper use of amino acids and organic cation transporter neurotransmitter optimization in treatment of depression. Antiaging |
